Effect of inhaled iloprost during off-medication time in patients with pulmonary arterial hypertension

被引:8
|
作者
Mereles, Derliz
Ewert, Ralf
Lodziewski, Sven
Borst, Mathias M.
Benz, Andreas
Olschewski, Horst
Gruenig, Ekkehard
机构
[1] Heidelberg Univ, Dept Internal Med 3, Heidelberg, Germany
[2] Med Univ Greifsward, Dept Pneumol, Greifsward, Germany
[3] Med Univ Graz, Div Pulm, Graz, Austria
关键词
pulmonary hypertension; iloprost; invasive monitoring;
D O I
10.1159/000101953
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: Iloprost is a stable prostacyclin analogue that is associated with a longer duration of vasodilatation and has been approved for inhalative use with 6 or 9 inhalations during the daytime and a night pause. It is not known if during the night pause rebound pulmonary hypertension occurs. Objectives: The aim of this study was to assess the hemodynamics in iloprost-treated patients during the daytime and at night. Methods: We enrolled 5 adult patients (aged 45 +/- 10 years) with idiopathic pulmonary arterial hypertension (IPAH) and chronic inhaled iloprost therapy for at least 12 months. Further medication remained unchanged during the study period. Hemodynamics were monitored by right heart catheterization. Results: After 30-60 min of nebulized iloprost, mean pulmonary arterial pressures (PAP) decreased from 68 +/- 15 to 51 +/- 18 mm Hg (p = 0.004). After 6 h off-medication sleeping time, mean PAP initially increased until 2 a.m. and decreased subsequently until wake-up time at 6 a.m. Mean PAP, cardiac index and pulmonary vascular resistance at night were not significantly different from the values during the day. Conclusions: In this study, patients with IPAH and chronic nebulized iloprost therapy did not reveal a rebound pulmonary hypertension during off-medication sleeping time. Copyright (c) 2007 S. Karger AG, Basel
引用
收藏
页码:498 / 502
页数:5
相关论文
共 50 条
  • [1] Inhaled iloprost in pulmonary arterial hypertension
    Baker, SE
    Hockman, RH
    ANNALS OF PHARMACOTHERAPY, 2005, 39 (7-8) : 1265 - 1274
  • [2] Inhaled iloprost for therapy in pulmonary arterial hypertension
    Ewert, Ralf
    Glaeser, Sven
    Bollmann, Tom
    Schaeper, Christoph
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2011, 5 (02) : 145 - 152
  • [3] Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension
    Hoeper, M. M.
    Leuchte, H.
    Halank, M.
    Wilkens, H.
    Meyer, F. J.
    Seyfarth, H. J.
    Wensel, R.
    Ripken, F.
    Bremer, H.
    Kluge, S.
    Hoeffken, G.
    Behr, J.
    EUROPEAN RESPIRATORY JOURNAL, 2006, 28 (04) : 691 - 694
  • [4] Inhaled Iloprost for patients with pulmonary arterial hypertension and right heart failure
    Martischnig, A. M.
    Tichy, A.
    Nikfardjam, M.
    Heinz, G.
    Lang, I.
    Bonderman, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2010, 181
  • [5] Rapid Transition from Inhaled Iloprost to Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension
    Bourge, Robert C.
    Tapson, Victor F.
    Safdar, Zeenat
    Benza, Raymond L.
    Channick, Richard N.
    Rosenzweig, Erika B.
    Shapiro, Shelley
    White, Richard James
    McSwain, Christopher Shane
    Gotzkowsky, Stephen Karl
    Nelsen, Andrew C.
    Rubin, Lewis J.
    CARDIOVASCULAR THERAPEUTICS, 2013, 31 (01) : 38 - 44
  • [6] Acute effects of inhaled iloprost on intracardiac conduction in patients with pulmonary arterial hypertension
    Yildiz, Mustafa
    Kahraman, Serkan
    Surgit, Ozgur
    Agus, Hicaz Zencirkiran
    Uygur, Begum
    Demir, Ali R.
    Kalkan, Mehmet E.
    Sancar, Kadriye Memic
    Oner, Ender
    Gurbak, Ismail
    Kalkan, Ali K.
    HERZ, 2022, 47 (02) : 158 - 165
  • [7] Switching inhaled iloprost formulations in patients with pulmonary arterial hypertension: the VENTASWITCH Trial
    Richter, Manuel J.
    Stollfuss, Barbara
    Roitenberg, Alexander
    Kleinjung, Frank
    Graeff, Valentin
    Berghaus, Sabine
    Mueller, Christian
    Ghofrani, Hossein-Ardeschir
    PULMONARY CIRCULATION, 2018, 8 (04)
  • [8] Combined treatment of sildenafil and inhaled iloprost in pediatric patients with severe pulmonary arterial hypertension
    Efren Santos-Martinez, Luis
    Jimenez-Santos, Moises
    Guillermo Arenas-Fonseca, Jorge
    Moreno-Gonzalez, Agustina
    Elena Medina-Concebida, Luz
    ARCHIVOS DE CARDIOLOGIA DE MEXICO, 2015, 85 (01): : 80 - 84
  • [9] Transitioning from IV/SQ prostanoids to inhaled iloprost in patients with pulmonary arterial hypertension
    Saggar, Rajeev
    Sulica, Roxana
    Williamson, Timothy
    Kim, Nick H.
    Channick, Richard N.
    CHEST, 2006, 130 (04) : 257S - 258S
  • [10] Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension
    Wilkens, H
    Guth, A
    König, J
    Forestier, N
    Cremers, B
    Hennen, B
    Böhm, M
    Sybrecht, GW
    CIRCULATION, 2001, 104 (11) : 1218 - 1222